SOUTH SAN FRANCISCO, Calif., May 15, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended March 31, 2012. Net loss for the three months ended March 31, 2012 was $13.9 million, which included a non-cash expense of $4.9 million related to the revaluation of certain warrants. As of March 31, 2012, cash, cash equivalents and marketable securities totaled $34.9 million.
